TEMCELL

TOKYO: JCR Pharmaceuticals Co., Ltd. has withdrawn its application with the Ministry of Health, Labour and Welfare of Japan for additional marketing approval of TEMCELL HS Inj., allogeneic bone marrow-derived mesenchymal stem cells, for the indication of epidermolysis bullosa (EB)….